Alpine’s pipeline

We expect to file our first IND in 2018.

ProgramDiscoveryIn vitro POCIn vivo POCClinical Candidate SelectedINDTherapeutic Area
TIP™/SIP
TIP: Undisclosed TargetsOncology
SIP: Undisclosed TargetsOncology
Soluble vIgD™
ALPN-101 (Fc-ICOS/CD28)Inflammation
Multi-Target Checkpoint InhibitorOncology
Localized vIgD™
V-mAb ICOSLOncology
Other targetsOncology